FENC Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 4.41%, SMA50 9.14%, SMA200 4.48%). The stock’s 14-day RSI is 58.41 (neutral), while the ATR of 0.41 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -13.21% below its high and over 83.97% above its low. Average 10-day trading volume of 185.80 thousand shares is below the 3-month average of 227.90 thousand, indicating normal recent market interest.

Fennec Pharmaceuticals Inc. generated EPS of -$0.24 over the past year. Five-year average earnings growth is 52.21%. The latest quarter delivered EPS of $0.05. The next quarter is forecast at $0.04. Next year's EPS is expected at $139.26. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $13.00. The high target offers 69.49% upside. The low target suggests 22.41% downside. The mean target is $15.67. This offers 47.55% upside. Fennec Pharmaceuticals Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by 150.0%. The prior quarter beat by -150.0%. Over the last six quarters, Apple has recorded several small beats. These include -66.67% in May 13, 2025.

Fennec Pharmaceuticals Inc. has 35.07 million shares outstanding. The public float is 19.78 million shares, elevated short interest at 2.03% of float. This equals 615.87 thousand shares. The short ratio is 4.07 days. Institutional investors hold 63.5% of the float. Insiders own 14.46%. Essetifin SPA holds 3.99 million shares, Southpoint Capital Advisors LP has 2.74 million shares and MANCHESTER MANAGEMENT PR, LLC has 1.25 million shares. Over the past six months, insider transactions show net selling. They sold 171.96 thousand shares across 10 transactions.

Fennec Pharmaceuticals Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$10.06. This means the shares are trading below this model’s fair value.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) closed at $10.90 USD, gaining $0.28 (2.67%) from the previous close of $10.62. The stock is currently mid-range between its 52-week high and low $5.65 and $13.25. With a market capitalization of about $378.74 million, Fennec Pharmaceuticals Inc. is classified as a small-cap and shows market-like volatility (beta ~1.10). Key stats such as the average daily volume over the past year has been around 228.47 thousand shares, volume is running light vs its 52-week average. Headquartered in Research Triangle Park, NC, Fennec Pharmaceuticals Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jeffrey S. Hackman, the company employs approximately 35 people and listed since September 15, 2017. Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm.

Fennec Pharmaceuticals Inc. trades at a P/E ratio of -81.69, slightly below the S&P 500 average, with a price-to-sales ratio of 6.23 and a price-to-book ratio of 8.64 trading at moderately above to book value. The P/FCF stands at -180.84, also below market averages.

Our AI price prediction model suggests that Fennec Pharmaceuticals Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.13%, with price expected at $9.65 by October 02, 2026, within a range of $9.05 to $10.21 3-Month Outlook: Projected fall of -18.17%, reaching $8.69 by December 17, 2026, with a range of $8.49 to $8.87. 1-Year Outlook: Projected gain of 243.41%, with price at $36.47 by September 17, 2027, within a range of $36.16 to $47.06.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) shares are flat -4.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Fennec Pharmaceuticals Inc. trading at a premium to the broader market with a P/E of -81.69. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.48, suggesting 45.76% upside. Our AI forecast model points to short-term weakness (-9.13% over two weeks), a medium-term fall (-18.17% over three months), and a longer-term gain (243.41% over one year), with expected trading ranges indicating moderate volatility.